Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical‑stage biopharmaceutical company developing therapies to treat fibrotic diseases. The company focuses on fibrotic tissue–specific inhibition of integrins to modulate the TGF‑β pathway, with the goal of blocking pathological fibrosis while minimizing systemic toxicity. Pliant is advancing a pipeline of drug candidates across organ‑specific fibrotic indications and uses targeted biology and translational development to move programs through clinical trials.